A High-Throughput Enzyme-Coupled Activity Assay to Probe Small Molecule Interaction with the dNTPase SAMHD1
April 16th, 2021
SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase with critical roles in human health and disease. Here we present a versatile enzyme-coupled SAMHD1 activity assay, deployed in a 384-well microplate format, that allows for the evaluation of small molecules and nucleotide analogues as SAMHD1 substrates, activators, and inhibitors.
This method allows us to characterize which chemotherapy drugs are hydrolyzed by SAMHD1 and can be used as a screening assay to identify small molecule inhibitors of this enzyme. The main advantage of this technique is that it is simple, inexpensive, and yields vast amount of information about how different small molecules interact with this enzyme. Demonstrating the procedure will be Miriam, a postdoc from the group.
To begin, prepare complete SAMHD1 reaction buffer by adding Tween-20 and TCEP to the final concentrations of 0.005%and 0.3 millimolar respectively. Prepare EDTA stop solution by adding EDTA to a final concentration of 7.9 millimolar in complete SAMHD1 reaction buffer. Prepare malachite green, or MG working solution by mixing 10 parts of MG stock solution with 2.5 parts of 7%ammonium molybdate and 0.2 parts of 11%Tween-20.
Using a multichannel pipette, serially dilute test compounds in the relevant solvent at 100 times the final concentration in a clear round bottom polypropylene 96-well plate. further dilute these compounds to 25 times the final concentration with complete SAMHD1 reaction buffer to maintain the final solvent concentration below 1%Transfer five microliters of diluted component to the appropriate wells of a clear 384-well flat bottomed assay plate and repeat the procedure with solvent only control samples. For the enzyme master mix preparation, dilute recombinant human SAMHD1 protein and recombinant pyrophosphatase in complete SAMHD1 reaction buffer to four times the desired final concentration.
Prepare activator or substrate dGTP by diluting the solution in complete SAMHD1 reaction buffer to attain 50 micromolar concentration. To the wells containing compound dilutions and solvent only control, dispense five microliters of SAMHD1 pyrophosphatase master mix, and to the no enzyme control wells, add five microliters of complete SAMHD1 reaction buffer. Then dispense 10 microliters of dGDP solution into all wells to start the reaction and incubate for 20 minutes at room temperature.
To stop the reaction, add 20 microliters EDTA stop solution. After adding 10 microliters of MG working solution to all the wells, mix the content using an orbital microwell plate shaker and centrifuge the plate at 1000 x g for one minute. Incubate the plate for 20 minutes at room temperature and read the absorption at 630 nanometers in a microwell plate reader.
Calculate the standard deviation of the positive control wells and then calculate the average. Similarly for the negative control wells, calculate the standard deviation and then calculate the average. Calculate the Z factor is an indicator of the assay quality.
Normalize each absorbance value to the mean values of positive and negative controls. Setting the positive control as 100%SAMHD1 activity and the negative control as 0%SAMHD1 activity. Plot SAMHD1 activity is a function of compound concentration and fit a four parameter variable slope dose response curve, allowing determination of the compound's half maximal inhibitory concentration.
Dilute nucleotide analog stocks and complete SAMHD1 reaction buffer to four times the final concentration and transfer five microliters to the appropriate wells of a 384-well assay plate. To prepare enzyme SAMHD1 or pyrophosphatase master mix, dilute recombinant human SAMHD1 protein and Escherichia coli pyrophosphatase in complete SAMHD1 reaction buffer to twice the desired final concentration. Prepare only pyrophosphatase solution by diluting recombinant Escherichia coli pyrophosphatase to twice the desired final concentration in complete SAMHD1 reaction buffer.
Similarly, prepare activators GTP and dGTP alpha S by diluting the stock in complete SAMHD1 reaction buffer to four times the final concentration. Dispense five microliters of the activator, either GDP or dGTP alpha S or complete SAMHD1 reaction buffer to the appropriate wells of a 384-well assay plate containing the nucleotide analogs. Start the reaction by dispensing 10 microliters of SAMHD1 pyrophosphatase master mix, pyrophosphatase alone or complete SAMHD1 reaction buffer to the appropriate wells and incubate for 20 minutes at room temperature.
After stopping the reaction using EDTA stop solution, add 10 microliters of MG working solution to all the wells. Once the contents are mixed, centrifuge the plate at 1000 x g for one minute and incubate for 20 minutes at room temperature. Then measure the absorbance at 630 nanometers.
Calculate the average absorbance values for the pyrophosphatase only reaction wells, which will be the background value. Then subtract the background value from the corresponding wells in the SAMHD1 or pyrophosphatase reactions. Finally, plot the corrected absorbance values for each nucleotide analog with buffer GTP and dGTP alpha S conditions.
In the present study, the absorbent increased with increasing sodium phosphate concentration following incubation with malachite green reagent and reached saturation at 0.25 millimolar concentration. The linear detection range of phosphate is visible from 0.004 to 0.03 millimolar. The requirement of assay components to achieve measurable SAMHD1 activity is illustrated.
Neither SAMHD1 nor pyrophosphatase alone could generate an organic phosphate in the presence of dGTP. However, when all the assay components were present, an increase in signal was observed. The dose response curves obtained for SAMHD1 inhibitor compounds showed that increasing concentrations effectively inhibit SAMHD1 activity.
Hydroxyurea does not inhibit SAMHD1 activity in vitro, which was indicated by unaffected SAMHD1 activity with increasing hydroxyurea doses. dGTP binding to both allosteric sites activate SAMHD1, allowing subsequent hydrolysis of this nucleotide, whereas the other three canonical dNTPs first require GTP activation of the first allosteric site before they can bind the second allosteric site and then be hydrolyzed at the catalytic site. For nucleotide analogs, clofarabine triphosphate is an allosteric site two activator and a substrate as activity is observed in the presence of GTP.
Whereas cytarabine triphosphate is only able to occupy the catalytic site as dGTP alpha S is required to observe activity. No activity was observed with gemcitabine triphosphate. Following the identification of small molecules inhibiting SAMHD1 in this assay by physical approaches, such as thermal shift assays, can be used to interrogate target engagement.
The method here shown helped us understand which of the cancer drugs can be hydrolyzed by SAMHD1 and establish this enzyme as a potential therapeutical target to overcome drug resistance.
Overview
This article presents a robust, high-throughput enzyme-coupled malachite green assay for characterizing the activity and inhibition of Sterile alpha motif and HD domain-containing protein 1 (SAMHD1). The method enables indirect measurement of SAMHD1 activity by quantifying inorganic phosphate released during nucleotide hydrolysis, facilitating the study of small molecule interactions, including inhibitors and allosteric regulators, with this enzyme.
Key Study Components
Area of Science
- Biochemistry
- Enzymology
- Cancer pharmacology
Background
- SAMHD1 regulates intracellular deoxynucleoside triphosphate (dNTP) pools by hydrolyzing dNTPs.
- It is implicated in nucleotide metabolism, therapy resistance, and various pathologies.
- Understanding SAMHD1's regulation and function is critical for therapeutic development.
- Simple, high-throughput assays are needed to probe small molecule interactions with SAMHD1.
Purpose of Study
- To develop and demonstrate a simple, inexpensive, and high-throughput assay for SAMHD1 activity.
- To characterize known inhibitors and substrates of SAMHD1, including anticancer drugs.
- To elucidate mechanisms of SAMHD1 catalysis and regulation by allosteric activators.
Methods Used
- Preparation of SAMHD1 reaction buffer, EDTA stop solution, and malachite green working solution.
- Serial dilution of test compounds and controls in 384-well plate format.
- Enzyme reactions using recombinant human SAMHD1 and pyrophosphatase, with nucleotide substrates or analogs.
- Colorimetric detection of inorganic phosphate via malachite green reagent and absorbance measurement at 630 nm.
- Data normalization, calculation of Z factor for assay quality, and dose-response curve fitting to determine inhibitor potency.
Main Results
- The assay reliably detects SAMHD1 activity only when all components are present.
- Known SAMHD1 inhibitors show dose-dependent inhibition; hydroxyurea does not inhibit SAMHD1 in vitro.
- dGTP acts as an allosteric activator, while other dNTPs require GTP for activation.
- Clofarabine triphosphate functions as both an allosteric activator and substrate; cytarabine triphosphate requires dGTP analog for activity; gemcitabine triphosphate is not hydrolyzed.
- The assay can identify small molecule inhibitors and characterize substrate specificity.
Conclusions
- The enzyme-coupled malachite green assay is a powerful, high-throughput tool for studying SAMHD1 activity and inhibition.
- It enables screening of small molecule inhibitors and characterization of nucleotide analog interactions.
- This method supports the identification of SAMHD1 as a therapeutic target to overcome drug resistance in cancer.
Frequently Asked Questions
Executive Industry Relevance
High-throughput enzyme-coupled activity assays for SAMHD1 enable rapid, quantitative interrogation of small molecule interactions with a key regulator of nucleotide metabolism. This capability is critical for target validation, mechanistic de-risking, and portfolio triage in oncology and antiviral drug discovery pipelines. The malachite green assay format supports scalable screening and robust data generation for both inhibitor and substrate profiling.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic interrogation of SAMHD1 as a therapeutic target by quantifying small molecule modulation.
- Supports mechanistic de-risking through direct measurement of enzyme activity in response to candidate compounds.
- Facilitates functional validation of allosteric regulators and inhibitors relevant to drug resistance pathways.
Screening & Assay Development
- Provides a standardized, high-throughput platform for screening compound libraries against SAMHD1.
- Delivers reproducible, quantitative outputs suitable for dose-response and IC50 determination.
- Enables assay scalability and platform reuse across diverse compound classes and analogs.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by characterizing drug-enzyme interactions relevant to therapy resistance.
- Supports continuity from early discovery through preclinical validation of candidate inhibitors or substrates.
- Informs risk-adjusted advancement decisions by clarifying substrate specificity and inhibitor potency.
Pipeline & Workflow Integration
This assay integrates at the interface of target validation, lead identification, and preclinical mechanistic studies for nucleotide metabolism targets.
- Discovery Biology: Quantifies enzyme activity changes to test therapeutic hypotheses and clarify regulatory mechanisms.
- Screening: Provides robust, reproducible readouts for compound triage and hit validation.
- Analytics: Enables dose-response curve fitting, Z-factor calculation, and normalization for cross-condition comparison.
- Translational Research: Links in vitro enzyme modulation to potential in vivo drug resistance mechanisms.
- Enterprise Reuse: Adaptable to other phosphate-releasing enzymes for broader portfolio application.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target engagement and inhibitor efficacy.
- Operational Value: Streamlines assay setup, standardization, and high-throughput data acquisition.
- Strategic Value: Improves go/no-go decision quality and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of candidate molecules and mechanistic targets.
Implementation Considerations
- Requires expertise in enzymology, assay development, and quantitative data analysis.
- Needs access to recombinant protein production and high-throughput plate readers.
- Demands rigorous cross-team standardization of controls and normalization procedures.
- Adaptable to various nucleotide analogs and small molecule libraries with minimal protocol changes.
- Detection range and background correction must be validated for each new enzyme or substrate class.
